Presentation Information
[D2-B1-01]Considerations of ADA assay optimization for incretin peptide-based therapeutics in preclinical studies
*Ruoxuan Sun1, Janey Ronxhi1, Yipei Zhang1, Xiaobin Zhang1, Mark G Qian1 (1. Takeda Development Center Americas, Inc.)
Password required to view
Log in
or
Comment
To browse or post comments, you must log in.Log in